



To

Date: 14.08.2025

The Manager
BSE Limited
P. J. Towers, Dalal Street
Mumbai-400001

Dear Sir/ Madam,

Unit: Oxygenta Pharmaceutical Limited (Scrip: 524636)

Sub: Outcome of Board Meeting for the Un-audited financial results for quarter ended 30.06.2025 and other matters under Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

With reference to the subject cited, this is to inform the Exchange that the Board of Directors of **Oxygenta Pharmaceutical Limited** at its meeting held on Thursday, 14th August, 2025 at 3:00 P.M. at registered office of the Company for the quarter ended 30th June, 2025 considered and approved the following:

1. Un-audited Financial Results for the quarter ended 30th June, 2025. **(Attached)**
2. Limited Review Report for the quarter ended 30th June, 2025. **(Attached)**
3. Appointment of M/s. Suryachandra & Associates, Chartered Accountants, as Internal Auditors of the Company for the Financial Year 2025-26. **(Details annexed as Annexure A)**
4. Appointment of M/s. Aakanksha Dubey & Co., Practicing Company Secretaries as Secretarial Auditors of the Company. **(Details annexed as Annexure A)**
5. Appointment of M/s. PCR & Associates, Cost Accountants, as the Cost Auditors of the Company for the Financial Year 2025-26. **(Details annexed as Annexure A)**
6. Resignation of Ms. Dolly Mandhan as the Company Secretary & Compliance Officer of the Company w.e.f. 14th August, 2025. **(Details annexed as Annexure B)**
7. Appointment of Ms. Kumkum Bajaj as the Company Secretary & Compliance Officer of the Company w.e.f. 14th August, 2025. **(Details annexed as Annexure B)**
8. Took note of the Cost Audit Report for the Financial Year 2024-25.
9. Took note of the Secretarial Audit Report for the Financial Year 2024-25.

The Meeting concluded at 04:30 P.M.

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,
For Oxygenta Pharmaceutical Limited

Balasubba Reddy Mamilla
Executive Director
(DIN: 01998852)

OXYGENTA PHARMACEUTICAL LIMITED (Subsidiary of **VIRUPAKSHA ORGANICS LIMITED**)

(An ISO 9001:2015, ISO 14001:2018 and ISO 45001:2015 Certified Company)

Regd off. & Factory: Sy.No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist)-502 291, Telangana, INDIA. Tel: 08455-250080
Corp. Office: Level-1, Plot No. B1 & B2, IDA Gandhi Nagar, Kukatpally, Hyderabad – 500 037, Telangana, INDIA.

E-Mail id: info@oxygentapharma.com. Website: www.oxygentapharma.com,

Phone 040-23073417, CIN: L24110TG1990PLC012038

OXYGENTA PHARMACEUTICAL LIMITED

CIN: L24110TG1990PLC012038

Regd Office: Survey No. 252/1, Aroor Village, Sadasivapet Mandal, Sangareddy Dist, Telangana State

Corp Office: Level-1 Plot No B1 and B2, IDA Gandhi Nagar, Balanagar Township Hyderabad

Rangareddy, Telangana, India, 500037

Website: www.oxygentapharma.com, Email Ids: md@oxygentapharma.com, cs@oxygentapharma.com.in, Phone Number: 040- 23559938

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2025

(Rupees in Lakhs)

S.No	Particulars	Quarter ended			Year ended
		30.06.2025	31.03.2025	30.06.2024	31.03.2025
		Un Audited	Audited	Un Audited	Audited
1	Income				
	a. Revenue from operations	1,513.47	4,946.66	1,262.08	10929.86
	b. Other income	16.91	4.91	2.25	130.91
2	Total Income (a+b)	1530.37	4951.56	1264.33	11060.77
3	Expenses				
	a) Cost of Material Consumed	1,565.88	4,402.97	1,065.78	10,023.06
	b) Change in Inventories	(70.34)	(24.34)	(65.90)	(376.06)
	c) Direct Manufacturing Expenses	386.18	344.36	195.22	1,116.09
	d) Employee benefits expense	200.19	218.97	148.18	689.94
	e) Finance costs	62.84	212.82	40.68	178.16
	f) Depreciation and amortization expense	84.73	(23.37)	64.94	361.42
	g) Other expenses	114.51	168.05	97.13	471.27
	h) Prior Period Expenses	-	5.02	-	5.02
	Total Expenses	2,343.99	5,304.48	1,546.03	12,468.91
4	Profit before exceptional items and tax (2-3)	(813.62)	(352.92)	(281.70)	(1,408.14)
5	Exceptional items	1.18	27.00	-	27.00
6	Profit before Tax (4-5)	(814.80)	(379.93)	(281.70)	(1,435.14)
7	Tax expense				
	(1) Current tax	-	-	-	-
	(2) Deferred tax	(204.19)	(180.59)	(145.37)	(421.27)
	(3) Previous year Income tax adjustment	-	15.96	-	15.96
8	Net Profit/(Loss) for the Period (4-5)	(610.61)	(215.29)	(136.33)	(1,029.83)
9	Other comprehensive income (OCI)				
	(a) (i) Items that will not be reclassified to profit or loss	-	10.73	0.00	10.73
	(ii) Tax on items that will not be reclassified to profit or loss	-	0.00	-	0
	(b) (i) Items that will be reclassified to profit or loss	-	0.00	-	0
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	0.00	-	0
	Total Other Comprehensive income	-	10.73	-	10.73
10	Total Comprehensive income (6+7)	(610.61)	(226.02)	(136.33)	(1,040.55)
	Earnings per equity share				
	(Face value of Rs.10/- each)				
	(1) Basic	(1.65)	(0.60)	(0.39)	(2.86)
	(2) Diluted	(1.65)	(0.60)	(0.37)	(2.86)
	Paid- up equity share capital(Face Value of Rs.10/- each)	3,698.35	3,698.35	3,548.35	3698.35



Notes:

- 1.The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the companies (Indian Accounting standards) Rules, 2015 as amended by the companies (Indian Accounting standards) (Amendment) rules,2016.
- 2.The above Financial results recommended by the Audit Committee are considered and approved by the Board of Directors at their meeting held on 14th August 2025
- 3.The Statutory Auditors of the Company have carried out "Limited Review" of the above unaudited financial results and their Report has been placed before the Board at the said Meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015.
4. Total Revenue for the current quarter reported Rs 1513.47 Lakhs compared to Rs. 1262.08 lakhs for the corresponding quarter of the previous year.
5. The Loss before tax for the current quarter is Rs.814.80 Lakhs compared to Loss Before tax of Rs.281.70 Lakhs for the corresponding quarter of the previous year.
- 6.The Entire operations of the Company relate to only one segment i.e Manufacturing of Pharmaceutical Products., Hence, segmental reporting as per IND AS-108 is not made.
- 7.The results for the quarter ended 30th June 2025 are also available on the bomabay stock exchange website and on the Company's website.
- 8.Figures for the previous periods /year have been regrouped/reclassified wherever necessary.
9. The Company is actively working to complete the identification of its MSME creditors, though a few gaps remain in this process. To facilitate accurate identification, we have requested all suppliers to submit self-declaration forms confirming their MSME status. The Company is currently in the process of collecting these declarations from suppliers to enhance accuracy in reporting.
10. The Company has yet to implement a bill-to-bill adjustment process, which has posed challenges in preparing a precise aging schedule for its creditors. Addressing these outstanding issues remains a priority, and the Company is committed to achieving full compliance and transparency in its reporting.
13. The Exceptional items amounts to 1.18 lakhs as on 30th June 2025 includes the total amount of provident fund damages

For and on behalf of the Board of Directors
OXYGENTA PHARMACEUTICAL LIMITED
CIN: L24110TG1990PLC012038


BALASUBBA REDDY MAMILLA
Executive Director
DIN : 01998852



Place:Hyderabad
Date: 14-08-2025

**Independent Auditor's Review Report on Unaudited Quarterly Financial Results of
OXYGENTA PHARMACEUTICAL LIMITED Pursuant to the Regulation 33 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To,
The Board of Directors,
Oxygenta Pharmaceutical Limited.

1. We have reviewed the accompanying statement of unaudited financial results of Oxygenta Pharmaceutical Limited ("the Company") for the quarter ended June 30, 2025 and year to date results for the period April 01, 2025, to June 30, 2025 ("the Statement") attached herewith, being submitted by the company Pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation")
2. This Statement, which is the responsibility of the company's Management and approved by the Board of Directors, has been Prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting", prescribed under Section 133 of the companies act, 2013 read with relevant rules issued there under and other recognized accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the statement in accordance with the Standard of Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review Consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to

obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit Opinion.

4. Based on our review conducted and Procedures performed as stated in Paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Financial results prepared in accordance with the recognition and measurement principles laid down in IND AS 34, Prescribed under Section 133 of the Companies act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A.M REDDY & D.R REDDY

Chartered Accountants

Firms Registration No: 009068S

D. Rama Krishna Reddy

Partner

Membership No. 209211

UDIN: 25209211BMJBOV1461

Place: Hyderabad

Date: August 14, 2025



Annexure – A

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with clause 7 of Para A of Annexure I of SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024]

Particulars	Internal Auditor	Secretarial Auditors	Cost Auditors
Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment of M/s. Suryachandra & Associates, Chartered Accountants as Internal Auditors of the Company.	Appointment of Aakanksha Dubey & Co., Practicing Company Secretaries, as Secretarial Auditors of the Company.	Appointment of PCR & Associates, Cost Accountants, as Cost Auditors of the Company.
Date of appointment & Terms of appointment	Date of appointment: 14.08.2025 Terms of appointment: Appointed for the Financial Year 2025-26 at terms as recommended by the Nomination and Remuneration Committee and approved by the Board of Directors.	Date of appointment: 14.08.2025 Terms of appointment: Appointed for the period of five (5) financial year(s) i.e. from 2025-26 to 2029-30 subject to the approval of shareholders.	Date of appointment: 14.08.2025 Terms of appointment: Appointed for the Financial Year 2025-26 at terms as recommended by the Nomination and Remuneration Committee and approved by the Board of Directors, subject to the ratification of shareholders.
Brief Profile	M/s. Suryachandra & Associates, Chartered Accountants is dedicated to providing personalized solutions that cater to the unique needs of each client. We are experts in handling Statutory and Internal Audits, Direct Taxation, Goods & Services Tax (GST), Corporate Laws, and Financial Planning. Our approach is to simplify complex financial issues, offering clear, effective advice and services.	M/s. Aakanksha Dubey & Co., Practicing Company Secretaries are having equivalent and substantial experience in corporate secretarial functions and compliance frameworks applicable to listed and unlisted companies and have handled a wide range of secretarial assignments.	PCR & Associates is a leading Cost Accountancy firm rendering comprehensive professional services which include Cost Audit, Management Consultancy, Tax Consultancy, Cost Accounting Services, Manpower Management, Secretarial Services etc.
Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable	Not Applicable	Not Applicable

OXYGENTA PHARMACEUTICAL LIMITED (Subsidiary of **VIRUPAKSHA ORGANICS LIMITED**)

(An ISO 9001:2015, ISO 14001:2018 and ISO 45001:2015 Certified Company)

Regd off. & Factory: Sy.No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist)-502 291, Telangana, INDIA. Tel: 08455-250080
Corp. Office: Level-1, Plot No. B1 & B2, IDA Gandhi Nagar, Kukatpally, Hyderabad – 500 037, Telangana, INDIA.

E-Mail id: info@oxygentapharma.com. Website: www.oxygentapharma.com,

Phone 040-23073417, CIN: L24110TG1990PLC012038

Annexure- B

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with clause 7 of Para A of Annexure I of SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024]

Particulars	Ms. Dolly Mandhan	Ms. Kumkum Bajaj
Reason for change viz. appointment, resignation, removal, death or otherwise	Resignation: Resignation of Ms. Dolly Mandhan as Company Secretary and Compliance officer of the Company.	Appointment of Ms. Kumkum Bajaj as Company Secretary and Compliance officer of the Company.
Date of appointment & Terms of appointment	Resignation of Ms. Dolly Mandhan as Company Secretary and Compliance officer of the Company w.e.f. 14.08.2025	Appointment of Ms. Kumkum Bajaj as Company Secretary and Compliance officer of the Company w.e.f. 14.08.2025.
Brief Profile	Not Applicable	Ms. Kumkum Bajaj is a qualified Company Secretary and Associate Member of the Institute of Company Secretaries of India. She has working knowledge in handling Secretarial and Compliance matters.
Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable	Ms. Kumkum Bajaj is not related to any of the Directors or Key Managerial Personnel or Promoters of the Company.

Date: 14.08.2025

To,
The Board of Directors
Oxygenta Pharmaceutical Limited
Survey No.252/1,Aroor village,
sadasivapet mandal, Medak District,
Medak, Telangana, India.

Dear Sir / Madam,

Sub: Resignation from the post of Company Secretary & Compliance Officer

I, Dolly Lakhichand Mandhan having membership No. A66040, hereby tender my resignation from the Post of Company Secretary & Compliance Officer of the Company with effect from August 14, 2025 due to my pre-occupation and personal obligations. The board is requested to consider and take note on record my resignation letter.

I would like to thank the Board and the management of the company for their support and guidance during my association with the Company which has helped me grow professionally.

I request the Board of Directors to take the necessary steps including intimation to the Stock Exchange and filling the necessary forms with the concerned Registrar of Companies.

Thanking you,
Yours Sincerely,



Signature:
Dolly Lakhichand Mandhan
Membership No. A66040